New Shareholders for Medicortex
3.3.2023 13:30:00 EET | Medicortex Finland Oyj | Press release
More than half of the investments in the round came from new investors which means that the company has currently a total of 267 shareholders. Last autumn Medicortex signed a 2 million dollars research grant contract with the US Department of Defense (DoD) to develop a prototype of a rapid test for detection of mild traumatic brain injury or concussion in urine samples.
“While the contract with the DoD supports the main product development activities for the coming year, the grant is bound to the activities presented in the project plan. The funds raised in the share issue enable us to activate parallel initiatives to pave the way for the future products.” says Dr. Adrian Harel, CEO of Medicortex. “Continuous support from many old shareholders together with the public interest and investments by a fair number of new investors indicate that we are on the right path.” Dr. Harel concludes.
Keywords
Contacts
Adrian HarelCEO
Tel:+358 400 488 817adrian.harel@medicortex.fiLinks
About Medicortex Finland Oyj
Medicortex Finland OyjMedicortex Finland Oyj is a biotechnology company dedicated to improving the diagnostics and treatment of Traumatic Brain Injury (TBI). Its current focus is on developing biomarker diagnostics to detect brain injury easily. The company has technology to capture biomarkers from urine and saliva and capability to develop an affordable diagnostic tool to detect biomarkers. Company's second goal is to develop new compounds to serve as drug candidates to halt progression of brain injury and reduce the secondary degeneration. Medicortex was founded by an Israeli Neurobiologist Adrian Harel (PhD, MBA) and the company is based in Turku, Finland.
Subscribe to releases from Medicortex Finland Oyj
Subscribe to all the latest releases from Medicortex Finland Oyj by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Medicortex Finland Oyj
Medicortex Finland Oyj Welcomes NGM’s Conditional Approval for Continued Listing of the Combined Group22.6.2026 08:31:59 EEST | Press release
Medicortex Finland Oyj (“Medicortex Finland”) today comments on the announcement that Nordic Growth Market NGM AB (“NGM”) has granted conditional approval for NOSIUM AB (publ) — which is in the process of changing its name to Medicortex International AB (publ) — to continue trading on NGM Growth Market following completion of its reverse takeover of Medicortex Finland.
Medicortex now trademarked12.6.2026 08:20:00 EEST | Press release
The Finnish biotechnology company Medicortex Finland Plc announces approval of the trademark MedicortexTM by the European Union Intellectual Property Office (EUIPO).
A European patent granted for Medicortex11.12.2025 17:00:00 EET | Press release
The European Patent Office (EPO) has granted a patent for Medicortex Finland Oyj, a biopharmaceutical company focusing on development of diagnostics and treatments for traumatic brain injury (TBI). The patent strengthens Medicortex's unique approach for detection of glycan-based indicators of brain trauma.
Medicortex Signs a Share Purchase Agreement (SPA) with Nosium Ab (publ) – Strengthens Path Toward Commercializing TBI Diagnostics24.11.2025 10:13:02 EET | Press release
Medicortex Finland Oyj (“Medicortex”), together with its majority shareholders, has signed a binding SPA with Nosium Ab (publ) (“Nosium”), marking a significant step toward advancing the commercialization of Medicortex’s rapid diagnostic tests for traumatic brain injury (TBI). Under the agreement, Nosium intends to acquire up to 89.9 percent of Medicortex at a valuation of EUR 1 per share. The agreement underscores strong confidence in Medicortex’s biomarker-based, non-invasive diagnostic approach for TBI.
A patent granted for Medicortex28.8.2025 12:00:00 EEST | Press release
Medicortex Finland Plc, a biopharmaceutical company focusing on development of diagnostics and drugs for mild traumatic brain injury (TBI), was granted a patent in Israel for company’s innovative method and device for non-invasive detection of TBI.